Stevens-Johnson Syndrome and Toxic epidermal necrolysis a 15-year retrospective study;Síndroma de Stevens-Johnson e Necrólise Tóxica Epidérmica um estudo retrospectivo de 15 anos

Acta Medica Portuguesa

Volumn 24, Issue 1, 2011, Pages 59-70

  Moniz, Paula ^a   Casal, Diogo ^a   Mavioso, Carlos ^a   Castro, José Videira E ^a   Almeida, Maria Angélica ^a  

^a HOSPITAL DE SÃO JOSÉ   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; HUMAN; INFECTION RATE; LENGTH OF STAY; MORTALITY; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; AGED; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME; TIME FACTORS; YOUNG ADULT;

EID: 79953236968     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. BASTUJI-GARIN S, FOUCHARD N, BERTOCCHI M, ROUJEAU JC, REVUZ J, WOLKENSTEIN P: SCORTEN: a severity- of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-153
2. FRENCH LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006;55:9-16
3. BARONI A, RUOCCO E: Lyell's syndrome. Skinmed 2005;4:221-5
4. CABRAL L, DIOGO C, RIOBOM F, TELES L, CRUZEIRO C: [Toxic Epidermal Necrolysis (Lyell syndrome): a pathology for burn units]. Acta Med Port 2004;17:129-140
5. AUQUIER-DUNANT A, MOCKENHAUPT M, NALDI L, CORREIA O, SCHRODER W, ROUJEAU JC: Correlations between clinical patterns and causes of erythema multiforme majus, Stevens- Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019-24
6. JACKSON R: Sir Jonathan Hutchinson on toxic epidermal necrolysis - an historical note. Br J Dermatol 1974;91:469-541
7. Lyell A: Toxic Epidermal Necrolysis: An eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-361
8. FAGAN S, SPIES M, HOLLYOAK M, MULLER MJ, GOODWIN CW, HERNDON DN: Exfoliative and necrotizing diseases of the skin. In Total Burn Care. Third edition. Edited by Herndon DN. Philadelphia: Saunders Elsevier 2007;554-565
9. BRAMBILLA G, BRUCATO F, ANGRISANO A, PALMIERI G: Treatment of toxic epidermal necrolysis (TEN). Ann Burns Fire Disasters 2002;15:17-21
10. CASTANA O, MAKRODIMOU M, MICHELAKIS D, TSANDOULAS Z, ALEXAKIS D: Diseases mimicking a burnoutcome and treatment. Ann Burns Fire Disasters 2005;18:130-2
11. AHMAD FU, MAHAPATRA AK: Phenytoin-induced toxic epidermal necrolysis in a neurosurgical patient. Neurol India 2007;55:181-2
12. ARIF H, BUCHSBAUM R, WEINTRAUB D et al: Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-9
13. RZANY B, HERING O, MOCKENHAUPT M et al: Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996;135:6-11
14. PAUL C, WOLKENSTEIN P, ADLE H et al: Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-4
15. VERNEUIL L, RATAJCZAK P, ALLABERT C et al: Endothelial cell apoptosis in severe drug-induced bullous eruptions. Br J Dermatol 2009;161:1371-75
16. AOYAMA Y, KOUCHI K, HIRAMITSU Y, IWATA H, KITAJIMA Y: Generalized eruption with histopathologic toxic epidermal necrolysis caused by occupational exposure to thiourea dioxide. Eur J Dermatol 2009;19:509-511
17. AMIN R, SMIT E, SHAIKH G, RAWLING P, ALEXANDER E: Mycoplasma respiratory tract infection complicated by Stevens- Johnson syndrome and surgical emphysema. Acta Paediatr 2007;96:472.
18. LISSIA M, MULAS P, BULLA A, RUBINO C: Toxic epidermal necrolysis (Lyell's disease). Burns 2009
19. SHAMMAS MC, LAI EC, SARKAR JS, YANG J, STARR CE, SIPPEL KC: Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol 2010;149:203-213 e202
20. CORREIA O, DELGADO L, RAMOS JP, RESENDE C, TORRINHA JA: Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993;129:466-8
21. Cabral L, Riobom F, Diogo C, Teles L, C. C: TOXIC EPIDERMAL NECROLYSIS - LYELL'S SYNDROME. Ann Burns Fire Disasters 2004;XVII
22. ARAKI Y, SOTOZONO C, INATOMI T et al: Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol 2009;147:1004-11, 1011 e 1001
23. ARCA E, KOSE O, ERBIL AH, NISANCI M, AKAR A, GUR AR: A 2-year-old girl with Stevens-Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin. Pediatr Dermatol 2005;22:317-320
24. AREVALO JM, LORENTE JA, GONZALEZ-HERRADA C, JIMENEZ-REYES J: Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000;48:473-8
25. BACHOT N, REVUZ J, ROUJEAU JC: Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6
26. BACHOT N, ROUJEAU JC: Intravenous immunoglobulins in the treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol 2003;3:269-274
27. BARMAN KD, VERMA KK, AGRAWAL S, AGARWALLA A, RIJAL A: Stevens-Johnson syndrome with idiopathic thrombocytopenic purpura treated with dexamethasone pulse therapy. J Dermatol 2003;30:54-8
28. LEAUTE-LABREZE C, LAMIREAU T, CHAWKI D, MALEVILE J, TAIEB A: Diagnosis, classification and management of erythema multiforme and Stevens-Johnsons syndrome. Arch Dis Child 2000;83:347-352
29. UGBURO AO, TEMIYE EO, ILOMBU CA: A 12-year retrospective study of non-burn skin loss (burn-like syndromes) at a tertiary burns unit in a developing country. Burns 2008;34:637-643
30. FINE JD: Management of acquired bullous skin diseases. N Engl J Med 1995;333:1475-84
31. ATIYEH BS, DHAM R, YASSIN MF, EL-MUSA KA: Treatment of toxic epidermal necrolysis with moisture-retentive ointment: a case report and review of the literature. Dermatol Surg 2003;29:185-8
32. COLLIN B, MARSHALL T, HEAGERTY A: Scoring with SCORTEN. Arch Dermatol 2003;139:1215; author reply 1215-6
33. KHOO AK, FOO CL: Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996;22:275-8
34. ABE R: Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. J Dermatol Sci 2008;52:151-9
35. ABE R, SHIMIZU T, SHIBAKI A, NAKAMURA H, WATANABE H, SHIMIZU H: Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003;162:1515-20
36. AL-MUTAIRI N, ARUN J, OSAMA NE et al: Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004;43:847-851
37. BAMICHAS G, NATSE T, CHRISTIDOU F et al: Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 2002;6:225-8
38. UETA M, SOTOZONO C, INATOMI T, KOJIMA K, HAMURO J, KINOSHITA S: Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome. Br J Ophthalmol 2008;92:989-991
39. PAQUET P, PIERARD GE: New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited. Drug Saf 2010;33:189-212
40. KHALILI B, BAHNA SL: Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006;97:272-280; quiz 281-273,320
41. EGAN CA, GRANT WJ, MORRIS SE, SAFFLE JR, ZONE JJ: Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-461
42. VIARD I, WEHRLI P, BULLANI R et al: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3
43. GUBINELLI E, CANZONA F, TONANZI T, RASKOVIC D, DIDONA B: Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol 2009;36:150-3
44. FAMULARO G, DI DONA B, CANZONA F, GIRARDELLI CR, CRUCIANI G: Etanercept for toxic epidermal necrolysis. Ann Pharmacother 2007;41:1083-4
45. NAMAZI MR: Increased mortality in toxic epidermal necrolysis with thalidomide: corroborating or exonerating the pathogenetic role of TNF-alpha? Br J Dermatol 2006;155:842-3
46. PAQUET P, PIERARD GE, QUATRESOOZ P: Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005;136:205-216
47. GUEUDRY J, ROUJEAU JC, BINAGHI M, SOUBRANE G, MURAINE M: Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009;145:157-162
48. ALFIREVIC A, JORGENSEN AL, WILLIAMSON PR, CHADWICK DW, PARK BK, PIRMOHAMED M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813-8
49. UETA M, SOTOZONO C, INATOMI T, KOJIMA K, HAMURO J, KINOSHITA S: Association of IL4R polymorphisms with Stevens- Johnson syndrome. J Allergy Clin Immunol 2007;120:1457-9
50. UETA M, SOTOZONO C, TOKUNAGA K, YABE T, KINOSHITA S: Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007;143:367-8
51. UETA M, TOKUNAGA K, SOTOZONO C et al: HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 2008,14:550-5